On this page
Sterile Water
Water · Injection, Solution
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 206369-001 | STERILE WATER FOR INJECTION | LIQUID | STERILE WATER FOR INJECTION | Prescription | AP | ||
| 206369-002 | STERILE WATER FOR INJECTION | LIQUID | STERILE WATER FOR INJECTION | Discontinued | — |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | September 2, 2015 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251102). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingPharmacy Bulk Package — Not for Direct Infusion. FOR USE ONLY WITH AUTOMATED COMPOUNDING DEVICES.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Sterile Water for Injection, USP is indicated for use only as a solvent or diluent vehicle for parenterally administered drugs or solutions and as a source of water for parenteral fluid replenishment after suitable additives are introduced. For intravenous administration, an osmolar concentration not less than two-fifths (0.4) of the normal osmolarity of the extracellular fluid (280 mOsmol/liter) is essential to avoid intravascular hemolysis.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible. Sterile Water for Injection, USP in the Pharmacy Bulk Package is intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of Sterile Water for Injection, USP. DIRECTIONS FOR USE OF VIAFLEX PLASTIC PHARMACY BULK PACKAGE CONTAINER To Open Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly, if leaks are found, discard solution as sterility may be impaired. For compounding only, not for direct infusion. Preparation for Admixing 1. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). 2. Suspend container from eyelet support. 3. Remove plastic protector from outlet port at bottom of container. 4. Attach solution transfer set. Refer to complete directions accompanying set. Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. 5. VIAFLEX containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry. 6. Once container closure has been penetrated, withdrawal of contents should be completed without delay. After initial entry, maintain contents at room temperature (25°C/77°F) and dispense within 4 hours.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Sterile Water for Injection, USP is a hemolytic agent due to its hypotonicity. Therefore, it is contraindicated for intravenous administration without additives.
Warnings
openFDA Drug LabelingWARNINGS FOR DILUTION ONLY. Do not heat over 66°C (150°F). This preparation is solute-free and its entry into the circulation undiluted will cause hemolysis . Absorption of large amounts of Sterile Water for Injection, USP with additives can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Adverse Reactions
openFDA Drug LabelingReactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination. To report SUSPECTED ADVERSE REACTIONS, contact Medefil, Inc., at 1-630-682-4600 or www.medefilinc.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination. To report SUSPECTED ADVERSE REACTIONS, contact Medefil, Inc., at 1-630-682-4600 or www.medefilinc.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Drug Interactions
openFDA Drug LabelingSome drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available. When diluting or dissolving drugs, mix thoroughly and use promptly. Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion. Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available. When diluting or dissolving drugs, mix thoroughly and use promptly. Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion.
Description
openFDA Drug LabelingDESCRIPTION: Sterile Water for Injection, USP is a sterile, nonpyrogenic, solute-free preparation of distilled water for injection. It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration. The pH is 5.5 (5.0 to 7.0). Sterile Water for Injection contains no bacteriostat, antimicrobial agent or added buffer and is intended only for single dose injection after admixture with an appropriate solute or solution. When smaller amounts are required, the unused portion should be discarded. Sterile Water for Injection is a pharmaceutic aid (vehicle) and parenteral fluid replenisher after addition of an appropriate solute. Water for Injection, USP is chemically designated H 2 O. The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers ( free flex ® bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container’s chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.
Overdosage
openFDA Drug LabelingOVERDOSAGE Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of fluid overload except possibly in neonates or very small infants. In the event these should occur, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS , PRECAUTIONS and ADVERSE REACTIONS .
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Sterile Water for Injection, USP is supplied in a single-dose 1000 mL flexible plastic container (NDC 0409-7990-09 Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA , Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA and 0990-7990-09 , ). ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time. INSTRUCTIONS FOR USE To Open Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. To Add Medication Prepare additive port. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication. The additive port may be protected by covering with an additive cap. Mix container contents thoroughly. Preparation for Administration (Use aseptic technique) Close flow control clamp of administration set. Remove cover from outlet port at bottom of container. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton. Suspend container from hanger. Squeeze and release drip chamber to establish proper fluid level in chamber. Open flow control clamp and clear air from set. Close clamp. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture. Regulate rate of administration with flow control clamp. WARNING: DO NOT USE FLEXIBLE CONTAINER IN SERIES CONNECTIONS. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Revised: September, 2018 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA EN-4689
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: WATER. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | June 15, 2022 | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0517-3010-25 | 0517-3010 | American Regent, Inc. | 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-3010-25) / 10 mL in 1 VIAL, SINGLE-DOSE (0517-3010-01) | April 22, 2022 |
| 0517-3020-25 | 0517-3020 | American Regent, Inc. | 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-3020-25) / 20 mL in 1 VIAL, SINGLE-DOSE (0517-3020-01) | April 22, 2022 |
| 0338-0013-04 | 0338-0013 | Baxter Healthcare Company | 1000 mL in 1 BAG (0338-0013-04) | June 30, 1982 |
| 0338-0013-06 | 0338-0013 | Baxter Healthcare Company | 2000 mL in 1 BAG (0338-0013-06) | June 30, 1982 |
| 0338-0013-08 | 0338-0013 | Baxter Healthcare Company | 3000 mL in 1 BAG (0338-0013-08) | June 30, 1982 |
| 0338-0013-29 | 0338-0013 | Baxter Healthcare Company | 5000 mL in 1 BAG (0338-0013-29) | June 30, 1982 |
| 17271-750-07 | 17271-750 | Becton Dickinson and Company | 10 BAG in 1 CASE (17271-750-07) / 1000 mL in 1 BAG | February 28, 2020 |
| 72572-747-10 | 72572-747 | Civica, Inc. | 10 VIAL in 1 CARTON (72572-747-10) / 10 mL in 1 VIAL (72572-747-01) | February 23, 2022 |
| 63323-178-76 | 63323-178 | Fresenius Kabi USA, LLC | 10 BAG in 1 CASE (63323-178-76) / 1000 mL in 1 BAG | November 24, 2017 |
| 0404-9781-10 | 0404-9781 | Henry Schein, Inc. | 1 VIAL in 1 BAG (0404-9781-10) / 10 mL in 1 VIAL | August 28, 2025 |
| 0143-9339-12 | 0143-9339 | Hikma Pharmaceuticals USA Inc. | 12 BAG in 1 CASE (0143-9339-12) / 1000 mL in 1 BAG | May 5, 2023 |
| 0641-6147-10 | 0641-6147 | Hikma Pharmaceuticals USA Inc. | 10 VIAL in 1 CARTON (0641-6147-10) / 10 mL in 1 VIAL (0641-6147-01) | September 3, 2015 |
| 0641-6147-25 | 0641-6147 | Hikma Pharmaceuticals USA Inc. | 25 VIAL in 1 CARTON (0641-6147-25) / 10 mL in 1 VIAL (0641-6147-01) | September 3, 2015 |
| 0990-7118-07 | 0990-7118 | ICU Medical Inc. | 6 BAG in 1 CASE (0990-7118-07) / 2000 mL in 1 BAG | June 1, 2019 |
| 0990-7990-09 | 0990-7990 | ICU Medical Inc. | 12 POUCH in 1 CASE (0990-7990-09) / 1 BAG in 1 POUCH / 1000 mL in 1 BAG | October 1, 2019 |
| 64253-020-21 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-21) / 1 mL in 1 SYRINGE, PLASTIC | January 27, 2020 |
| 64253-020-23 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-23) / 3 mL in 1 SYRINGE, PLASTIC | January 27, 2020 |
| 64253-020-25 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-25) / 5 mL in 1 SYRINGE, PLASTIC | September 21, 2020 |
| 64253-020-30 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-30) / 10 mL in 1 SYRINGE, PLASTIC | January 27, 2020 |
| 64253-020-35 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-35) / 5 mL in 1 SYRINGE, PLASTIC | January 27, 2020 |
| 64253-020-52 | 64253-020 | Medefil, Inc. | 60 SYRINGE, PLASTIC in 1 BOX (64253-020-52) / 2.5 mL in 1 SYRINGE, PLASTIC | January 27, 2020 |
| 64253-020-91 | 64253-020 | Medefil, Inc. | 10 SYRINGE, PLASTIC in 1 BOX (64253-020-91) / 10 mL in 1 SYRINGE, PLASTIC | September 21, 2020 |
| 0517-3010 | 0517-3010 | American Regent, Inc. | — | April 22, 2022 |
| 0517-3020 | 0517-3020 | American Regent, Inc. | — | April 22, 2022 |
| 0338-0013 | 0338-0013 | Baxter Healthcare Company | — | June 30, 1982 |
| 17271-750 | 17271-750 | Becton Dickinson and Company | — | February 28, 2020 |
| 72572-747 | 72572-747 | Civica, Inc. | — | February 23, 2022 |
| 63323-178 | 63323-178 | Fresenius Kabi USA, LLC | — | November 24, 2017 |
| 0404-9781 | 0404-9781 | Henry Schein, Inc. | — | August 28, 2025 |
| 0143-9339 | 0143-9339 | Hikma Pharmaceuticals USA Inc. | — | May 5, 2023 |
| 0641-6147 | 0641-6147 | Hikma Pharmaceuticals USA Inc. | — | September 3, 2015 |
| 0990-7118 | 0990-7118 | ICU Medical Inc. | — | June 1, 2019 |
| 0990-7990 | 0990-7990 | ICU Medical Inc. | — | October 1, 2019 |
| 64253-020 | 64253-020 | Medefil, Inc. | — | January 27, 2020 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.